Description: Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients, as well as designs and develops nanoformed drug substance. It also offers STARMAP, as a secure online portal to perform large numbers of in-silico CESS experiments The company was founded in 2008 and is headquartered in Helsinki, Finland.
Home Page: www.nanoform.com
Cultivator II
Helsinki,
00790
Finland
Phone:
358 2937 00150
Officers
| Name | Title |
|---|---|
| Mr. Albert Alexander Haeggstrom | CFO & Director |
| Prof. Edward Olof Haeggstrom | Co-Founder & CEO |
| Mr. Henri von Haartman | Director of Investor Relations |
| Mr. Peter Hanninen | General Counsel & Chief Development Officer |
| Dr. David Rowe | Head of Manufacturing |
| Mr. Christian Jones | Chief Commercial Officer |
| Mr. Antonio Da Silva | Chief of Business Operations |
| Ms. Johanna Kause | Chief Quality Officer |
| Dr. Jamie Unwin | Vice President of Strategic Insight |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8297 |
| Price-to-Sales TTM: | 600.6412 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 174 |